Cardio3 BioSciences, a leader in engineered cell therapies with clinical programs initially targeting indications in cardiovascular disease and oncology, today announced its intention to conduct a registered public offering in the United States.
The timing, number of shares and price of the proposed offering have not yet been determined. A draft registration statement relating to these securities has been confidentially submitted to the U.S. Securities and Exchange Commission but has not yet become effective.
Cardio3 BioSciences’ product candidates and research programmes are based on the breakthrough proprietary Cardiopoiesis technology platform, which is based on fundamental research conducted at Mayo Clinic. To date, the company, present in Labiotech Map, has received €114.2M in funding, including €26.5M on Euronext Brussels and Paris in July 2013.